The analyzed factors were ERβ expression, tumor size, pathological grade, lymph node metastasis, chemotherapy, radiotherapy, endocrine therapy, ERα expression and human epidermal growth factor receptor (HER-2) expression. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.